Núria Buil‐Bruna

Brain exposure of the ATM inhibitor AZD1390 in humans—a positron emission tomography study

Aurelija Jučaitė, Per Stenkrona, Zsolt Cselényi et al. · Neuro-Oncology · 2020 · 63 citations · Full text

A Population Pharmacodynamic Model for Lactate Dehydrogenase and Neuron Specific Enolase to Predict Tumor Progression in Small Cell Lung Cancer Patients

Núria Buil‐Bruna, José M. López-Picazo, Marta Moreno et al. · The AAPS Journal · 2014 · 32 citations · Full text

Neuron Specific Enolase, Medicine, Lactate Dehydrogenase +9

Semimechanistic Cell-Cycle Type–Based Pharmacokinetic/Pharmacodynamic Model of Chemotherapy-Induced Neutropenic Effects of Diflomotecan under Different Dosing Schedules

Víctor Mangas‐Sanjuan, Núria Buil‐Bruna, Marı́a J. Garrido et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 28 citations

Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors

Núria Buil‐Bruna, Marion Dehez, Amandine Manon et al. · The AAPS Journal · 2016 · 22 citations · Full text

Progression-free Survival, Surgical Oncology, Endocrine Oncology +8

Abstract A094: Phase I modular study of AZD0156, a first-in-class oral selective inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib (AToM Study, Module 1)

Wassim Abida, Yung Jue Bang, Louise Carter et al. · Molecular Cancer Therapeutics · 2018 · 17 citations

Molecular Biology, Pathology, Pharmacotherapy +18